SUBSCRIBE
SUBSCRIBE

Novartis

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Novartis AG Takes Another Shot at Amgen with Third Biosimilar Filing
November 18, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Onco-Immunology Companies like Juno, Novartis AG, Kite Pharma Struggle to Mass Produce Custom Cancer Therapies
October 30, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Novartis AG Hopes to File 10 Big Biosimilars in the Next Three Years
October 27, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Novartis AG Doubles Down on Immuno-Oncology, Acquires Admune and Inks Deals With XOMA and Palobiofarma
October 21, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Novartis AG and Roche Executives Continue to Deny Merger Ambitions
October 12, 2015
 · 
3 min read
Job Trends
Novartis AG’s Alcon to Add 300 Jobs in $250 Million Atlanta Expansion for Contact Lens Manufacturing
October 6, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Policy
Novartis AG’s Second Copycat Drug Takes Aim at Amgen Again
October 2, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Troubled XOMA Nails Immuno-Oncology Pact Worth $530 Million+ With Novartis AG
October 1, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
Novartis AG Opens Up $53 Million Global Data Center at Alcon in Texas
September 30, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Business
Novartis AG Tries More Exec Level OTC Switches
April 25, 2012
 · 
1 min read
Novartis AG’s Gilenya Given Final Approval by UK’s Cost Agency
April 25, 2012
 · 
1 min read
FDA
Novartis AG Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing’s Disease
April 25, 2012
 · 
11 min read
Business
Novartis AG Quarterly Profit Drops as Diovan, OTC Sales Slump
April 24, 2012
 · 
1 min read
Drug Development
Sosei Group Corporation’s QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149
April 24, 2012
 · 
6 min read
Business
Novartis AG Plans $550 Million Manufacturing Plant in Switzerland
April 23, 2012
 · 
1 min read
Business
Incyte Corporation Announces EU Regulatory Milestone for Ruxolitinib; Triggering a $40 Million Milestone Payment From Novartis AG
April 20, 2012
 · 
11 min read
Drug Development
Novartis AG Halts Hepatitis C Drug Trial After Death
April 20, 2012
 · 
1 min read
European Medicines Evaluation Agency Supports Novartis AG’ Gilenya With Stronger Warning
April 20, 2012
 · 
1 min read
Policy
EU Regulator to Rule on Novartis AG’ MS Pill Gilenya Safety
April 18, 2012
 · 
1 min read
Load More